Fluid administration is widely used to treat hypotension in patients undergoing veno-venous extracorporeal membrane oxygenation (VV-ECMO). However, excessive fluid administration may lead to fluid overload can aggravate acute respiratory distress syndrome (ARDS) and increase patient mortality, predicting fluid responsiveness is of great significance for VV-ECMO patients. This prospective single-center study was conducted in a medical intensive care unit (ICU) and finally included 51 VV-ECMO patients with ARDS in the prone position (PP). Stroke volume index variation (ΔSVI), pulse pressure variation (PPV), stroke volume variation (SVV), baseline carotid corrected flow time (FTc), and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak) were taken before and after the Trendelenburg position or volume expansion. Fluid responsiveness was defined as a 15% or more increase in stroke volume index as assessed by transthoracic echocardiography after the volume expansion (VE). In our study, 33 patients (64.7%) were identified as fluid responders. Stroke volume index variation induced by the Trendelenburg position (ΔSVI), FTc, and ΔVpeak demonstrated superior predictive performance of fluid responsiveness. ΔSVI had an AUC of 0.89 (95% CI, 0.80-0.98) with an optimal threshold of 14.5% (95% CI, 12.5-21.5%), with the sensitivity and specificity were 82% (95% CI, 66-91%) and 83% (95% CI, 61-94%). FTc had an AUC of 0.87 (95% CI, 0.76-0.98) with an optimal threshold of 332ms (95% CI, 318-335ms), the sensitivity and specificity were 85% (95% CI, 69-93%) and 83% (95% CI, 61-94%), respectively. ΔVpeak showed an AUC of 0.83 (95% CI, 72-95), with a 10% optimal threshold (95% CI, 9-13%), sensitivity was 82% (95% CI, 66-91%) and specificity 78% (95% CI, 55-91%). ΔSVI, FTc and ΔVpeak could effectively predict fluid responsiveness in VV-ECMO patients with ARDS in the PP. Compared to ΔSVI and ΔVpeak, FTc is easier and more direct to acquire, and it does not require Trendelenburg position or VE, making it a more accessible and efficient option for assessing fluid responsiveness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41598-024-83038-7 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685402 | PMC |
Acta Neuropathol
January 2025
Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Gliomas are the most common brain tumor type in children and adolescents. To date, diagnosis and therapy monitoring for these tumors rely on magnetic resonance imaging (MRI) and histopathological as well as molecular analyses of tumor tissue. Recently, liquid biopsies (LB) have emerged as promising tool for diagnosis and longitudinal tumor assessment potentially allowing for a more precise therapeutic management.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Background: Small vessel disease (SVD) is a disorder of the brain's microvessels and a common cause of dementia and stroke. Evidence links normal ageing features to SVD progression, involving endothelial activation, pericyte dysfunction, BBB failure, and microglia response. Here, we aim to examine this relationship through a series of translational investigations.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
McGill University, Montreal, QC, Canada.
Background: Activation of the mTOR pathway is pivotal for microglia to induce and sustain neuroprotective functions (Ulland et al., 2017; Wang et al., 2022).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: APOEε4 significantly increases the risk of developing Alzheimer's disease (AD). Cognitively healthy APOEε4-carriers exist, suggesting potential protective mechanisms against APOEε4. We hypothesized that some APOEε4-carriers may have genetic variations protecting them from developing APOEε4-mediated AD pathology.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: P-tau217 has emerged as a compelling alternative to long-established p-tau181 to accurately measure tau modifications in biofluids in response to brain Abeta and tau deposition in Alzheimer's disease (AD). Understanding the specificity and significance of p-tau217 changes over AD stages is critical to interpret its potential response to treatments against Abeta and tau aggregation.
Methods: We measured p-tau217 phosphorylation by mass spectrometry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!